What Is Your Medspa Worth? Valuation & EBITDA Multiples

Medspa valuations cluster into tiers. A solo or two-provider practice generating $500K–$1M EBITDA typically trades at 3–5x EBITDA, reflecting execution risk and limited scalability. An established, multi-location or high-revenue practice ($2M–$5M EBITDA) commands 6–10x, especially if it has repeatable systems and demonstrable retention. Larger platforms or roll-up targets ($5M+ EBITDA) can reach 10–15x or higher, particularly if they show strong unit economics and geographic expansion potential. The highest multiples—approaching 15–20x—go to practices with exceptional margins (40%+ net), predictable recurring revenue (membership/subscription models), and proven management teams that can scale. These tiers reflect buyer confidence: smaller practices are riskier; larger ones with proven operations command premium pricing.

Revenue quality and predictability matter most. Recurring revenue—membership plans, loyalty programs, package prepayment—commands a premium because it's less dependent on new-patient acquisition. Practices with 50%+ recurring revenue often see a 1–2x multiple boost. Margin stability is next: a practice with consistent 35–40% EBITDA margins is worth more than one with volatile 20–30% margins, even at the same revenue level. Provider dependency cuts hard: if the owner-injector is the only revenue driver, buyers discount heavily (often 20–30% haircut) because they assume patient loss on transition. Practices with multiple trained providers, delegation to nurse injectors, and patient loyalty to the brand (not the person) command higher multiples. Growth trajectory matters: if you've grown 15–20% year-over-year, buyers project forward and pay up. Flat or declining practices trade at the low end of their tier. Payer mix and geography also factor in: urban, affluent markets with strong toxin/filler demand and low insurance dependency are more valuable than rural or price-sensitive markets. Operational systems—documented protocols, staff retention, vendor relationships, marketing efficiency—reduce buyer risk and justify a higher multiple.

Buyers don't use your tax return EBITDA. They add back owner compensation (salary + perks), one-time costs, and non-recurring expenses, then subtract normalized costs for a replacement owner and any inflated discretionary spending. A typical recast: start with net income, add back depreciation, interest, taxes, and owner salary (they'll pay a market-rate injector or manager), then deduct realistic rent, staff, and supply costs. If you've been running the practice lean—paying yourself $300K when a hired injector would cost $150K—buyers will normalize that downward, reducing your EBITDA and thus your valuation. Conversely, if you've been expensing personal items or running inefficient operations, a recast can actually increase EBITDA and your multiple. Bring clean financials and be prepared to explain every add-back; buyers will verify via tax returns and bank statements.

All-cash deals are rare in medspa M&A below $10M EBITDA. Most deals are mixed: 40–60% cash at close, with the remainder as a seller note (you finance part of the purchase, typically at 5–7% interest, over 3–5 years) or earnout (you receive additional payment if the practice hits revenue or EBITDA targets in years 2–3). Earnouts are double-edged: they can boost your headline valuation but tie your payout to buyer execution—and buyers often have incentives to cut costs post-close, which can hurt earnout achievement. Rollover equity is common in roll-up scenarios: you receive cash plus equity in the parent company, aligning your interests with growth but introducing illiquidity and risk. Read the earnout formula carefully: is it based on gross revenue (easier to hit) or EBITDA (harder, because the buyer controls costs)? Are there clawback provisions if you leave or if the buyer changes the business model? A $2M valuation at 5x EBITDA ($400K EBITDA) might be structured as $800K cash + $800K seller note + $400K earnout, meaning you don't see the full $2M unless you stay and the practice performs.

A term sheet should specify: purchase price (total and breakdown: cash/note/equity/earnout), EBITDA multiple (so you can benchmark), working capital adjustment (how much cash/receivables stay with the practice), seller note terms (rate, term, prepayment penalties), earnout formula (what metric, what threshold, how long), and representations and warranties (what you're guaranteeing about the business). Red flags: a multiple that's 2–3x below market for your tier (suggests buyer is lowballing or sees hidden risk), an earnout tied to metrics you can't control (e.g., buyer's ability to raise prices), a seller note with a prepayment penalty (locks you in), or vague language around post-close management (are you staying? for how long? at what comp?). Ask: What happens to staff and provider contracts? Are there non-competes? What's the buyer's plan for the practice—will they fold it into a larger platform, rebrand, or run it standalone? If you're staying, is your comp tied to performance, and are there clawback provisions? Get a lawyer to review; the difference between a good and bad deal structure can be worth 10–20% of your valuation.

Before you engage a broker or advisor, run your own valuation. Calculate your trailing 12-month EBITDA (use the recast method above), then apply a conservative multiple for your tier (e.g., 5x for an established single-location practice, 8x for a multi-location with strong systems). That's your floor. Research recent comps: follow news on medspa acquisitions (PE roll-ups like Sothys, Skin Wellness Collective, and others regularly announce deals; trade publications like Aesthetic Surgery Journal and Dermatology Times cover valuations). Talk to peers off the record—what multiples did they see? What was their deal structure? Understand your leverage: if you're the only provider, your multiple is capped; if you have a team, it's higher. If you're in a hot market with strong growth, you can command premium pricing. If you're considering a sale, start documenting your business now: clean financials, provider contracts, patient retention data, recurring revenue streams, and operational procedures. Buyers pay for clarity and reduced risk; the better your records, the higher your multiple.